首页> Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology> Investigation of the Interplay between Circulating Lipids and IGF-I and Relevance to Breast Cancer Risk: An Observational and Mendelian Randomization Study.

Investigation of the Interplay between Circulating Lipids and IGF-I and Relevance to Breast Cancer Risk: An Observational and Mendelian Randomization Study.

导出 OA

翻译打印收藏纠错

第一作者： Vanessa Y,Tan

第一单位： Medical Research Council (MRC) Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.;Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

作者： Vanessa Y,Tan ^[1] ; Caroline J,Bull ^[1] ; Kalina M,Biernacka ^[2] ; Alexander,Teumer ^[3] ; Tom G,Richardson ^[4] ; Eleanor,Sanderson ^[1] ; Laura J,Corbin ^[1] ; Tom,Dudding ^[5] ; Qibin,Qi ^[6] ; Robert C,Kaplan ^[7] ; Jerome I,Rotter ^[8] ; Nele,Friedrich ^[9] ; Uwe,Völker ^[10] ; Julia,Mayerle ^[11] ; Claire M,Perks ^[2] ; Jeff M P,Holly ^[2] ; Nicholas J,Timpson ^[12]

作者单位： Medical Research Council (MRC) Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.;Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom. ^[1] IGFs & Metabolic Endocrinology Group, School of Translational Health Sciences, Learning & Research Building, Southmead Hospital, Bristol, United Kingdom. ^[2] Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.;Department of Population Medicine and Lifestyle Diseases Prevention, Medical University of Bialystok, Bialystok, Poland. ^[3] Medical Research Council (MRC) Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.;Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.;Novo Nordisk Research Centre, Headington, Oxford, United Kingdom. ^[4] Medical Research Council (MRC) Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.;Bristol Dental School, University of Bristol, Bristol, United Kingdom. ^[5] Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York. ^[6] Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.;Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. ^[7] The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California. ^[8] Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany. ^[9] Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany. ^[10] Department of Medicine A, University Medicine Greifswald, Greifswald, Germany.;Department of Medicine II, University Hospital, LMU Munich, Munich, Germany. ^[11] Medical Research Council (MRC) Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom. N.J.Timpson@bristol.ac.uk.;Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom. ^[12]